208592-17-0

Usage

Uses

Used in Pharmaceutical Research:
1(2H)-Pyridineacetic acid, 3-hydroxy-4-methyl-2-oxo-, ethyl ester (9CI) is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential applications in treating a range of diseases.
Used in Organic Synthesis:
In the field of organic synthesis, 1(2H)-Pyridineacetic acid, 3-hydroxy-4-methyl-2-oxo-, ethyl ester (9CI) serves as a valuable building block for the creation of more complex molecules. Its reactivity and functional groups make it a versatile compound for constructing a variety of organic compounds with diverse applications.
Used in Drug Discovery:
1(2H)-Pyridineacetic acid, 3-hydroxy-4-methyl-2-oxo-, ethyl ester (9CI) is also employed in drug discovery processes, where its potential pharmacological properties are explored. Researchers investigate its interactions with biological targets to identify possible therapeutic applications, making it a promising candidate for the development of new medications.
Used in Chemical Compound Libraries:
1(2H)-Pyridineacetic acid, 3-hydroxy-4-methyl-2-oxo-, ethyl ester (9CI) is often included in chemical compound libraries, which are essential resources for high-throughput screening in drug discovery. These libraries enable researchers to rapidly test a large number of compounds for their potential biological activities, increasing the chances of identifying effective treatments for various diseases.

Upstream product

• 208592-16-9 (3-Hydroxy-4-morpholin-4-ylmethyl-2-oxo-2H-pyridin-1-yl)-acetic acid ethyl ester 
• 50-00-0 formaldehyd 
• 95215-70-6 1-ethoxycarbonylmethyl-3-hydroxy pyrid-2-one 

Relevant academic research and scientific papers

Synthetic studies into 3-hydroxy-2(1)-pyridinone based hexadentate metal(III) ion chelators

An improved synthesis and purification of the hexadentate chelators, N,N,N,-tris[2-(3-hydroxy-2-oxo-1,2-dihydropyridin-1-yl)acetamido]ethylamine, 8a and N,N,N,-tris[2-(3-hydroxy-4-methyl-2-oxo-1,2-dihydropyridin-1- yl)acetamido]ethylamine, 8b is described.

Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1 H)-pyridones to biomolecules the anticancer activity determining parameter

Hydroxypyr(id)ones are versatile ligands for the synthesis of organometallic anticancer agents, equipping them with fine-tunable pharmacological properties. Herein, we report on the preparation, mode of action, and in vitro anticancer activity of RuII- and Os II-arene complexes with alkoxycarbonylmethyl-3-hydroxy-2-pyridone ligands. The hydrolysis and binding to amino acids proceed quickly, as characterized by NMR spectroscopy and ESI mass spectrometry. However, the reaction with amino acids causes cleavage of the pyridone ligands from the metal center because the amino acids act as multidentate ligands. A similar behavior was also observed during the reactions with the model proteins ubiquitin and cytochrome c, yielding mainly [protein + M(η6-p-cymene)] adducts (M = Ru, Os). Notably the ligand cleavage of the Os derivative was significantly slower than of its Ru analogue, which could explain its higher activity in in vitro anticancer assays. Furthermore, the reaction of the compounds to 5′-GMP was characterized and coordination to the N7 of the guanine moiety was demonstrated by 1H NMR spectroscopy and X-ray diffraction analysis. CDK2/Cyclin A protein kinase inhibition studies revealed potent activity of the Ru and Os complexes.